Hsa_circ_0003611 hinders the transformation of mesenchymal stem cells into osteosarcoma cells through suppressing MYC by IGF2BP3 via m6A modification

Le résumé fourni par la source

Abstract Background Osteosarcoma (OS) is the most common non-hematogenous primary malignancy in the bone. Due to several origins of OS, 30–40% OS patients would experience recurrence and metastasis, with a 5-year survival rate of 20–30%. Mesenchymal stem cells (MSCs) transform into OS cells during the differentiation into osteoblasts, and circular RNA (circRNA) hsa_circ_0003611 might contribute to the differentiation of MSCs into osteoblasts. However, the role of hsa_circ_0003611 in the transformation of MSCs into OS cells is largely unknown. This study aims to investigate whether hsa_circ_0003611 tunes the transformation of MSCs into OS cells. Methods Here, human bone marrow mesenchymal stem cells (hBMSCs) with hsa_circ_0003611 stably silenced was constructed. Moreover, protein-RNA interaction was detected by RNA immunoprecipitation (RIP), and N 6 -methyladenosine (m 6 A) modification of hsa_circ_0003611 was determined using methylated RNA immunoprecipitation (MeRIP). Results The present study reveals that hsa_circ_0003611 level is almost absent in OS cells compared to that in osteoblasts and MSCs. Moreover, hsa_circ_0003611 silence enhances the transformation of MSCs into OS cells in vitro and triggered tumorigenicity of MSCs for OS in vivo. Mechanistically, silence of hsa_circ_0003611 promotes the transformation of MSCs into OS cells by activating MYC proto-oncogene, bHLH transcription factor (MYC) via insulin like growth factor 2 mRNA binding protein 3 (IGF2BP3). Moreover, hsa_circ_0003611 silence improves MYC mRNA stability by facilitating the association between IGF2BP3 and MYC mRNA in MSCs. Furthermore, m 6 A modification disrupts the association between hsa_circ_0003611 and IGF2BP3 to enhance the association between IGF2BP3 and MYC mRNA in MSCs. Conclusion In summary, these findings highlight the role of hsa_circ_0003611 in the transformation of MSCs into OS cells and provide novel targets and strategies for OS treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.